Literature DB >> 29894180

Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity.

Samuel Agyei Nyantakyi1, Ming Li2, Pooja Gopal2, Matthew Zimmerman3, Véronique Dartois3, Martin Gengenbacher3, Thomas Dick4,3, Mei-Lin Go1.   

Abstract

The inclusion of an azaspiroketal Mannich base in the membrane targeting antitubercular 6-methoxy-1- n-octyl-1 H-indole scaffold resulted in analogs with improved selectivity and submicromolar activity against Mycobacterium tuberculosis H37Rv. The potency enhancing properties of the spiro-fused ring motif was affirmed by SAR and validated in a mouse model of tuberculosis. As expected for membrane inserting agents, the indolyl azaspiroketal Mannich bases perturbed phospholipid vesicles, permeabilized bacterial cells, and induced the mycobacterial cell envelope stress reporter promoter p iniBAC. Surprisingly, their membrane disruptive effects did not appear to be associated with bacterial membrane depolarization. This profile was not uniquely associated with azaspiroketal Mannich bases but was characteristic of indolyl Mannich bases as a class. Whereas resistant mycobacteria could not be isolated for a less potent indolyl Mannich base, the more potent azaspiroketal analog displayed low spontaneous resistance mutation frequency of 10-8/CFU. This may indicate involvement of an additional envelope-related target in its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29894180      PMCID: PMC6043372          DOI: 10.1021/acs.jmedchem.8b00777

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

1.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

2.  Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension.

Authors:  Whitney L Petrilli; Scott B Hoyt; Clare London; Daniel McMasters; Andreas Verras; Mary Struthers; Doris Cully; Thomas Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Qing Chen; Ying Li; Elaine Tung; Wei Tang; Gino Salituro; Ian Knemeyer; Bindhu Karanam; Joseph Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Shipley; Douglas J MacNeil; Ruth Duffy; James R Tata; Feroze Ujjainwalla; Amjad Ali; Yusheng Xiong
Journal:  ACS Med Chem Lett       Date:  2016-11-22       Impact factor: 4.345

Review 3.  Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus.

Authors:  W Fischer
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

4.  Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition.

Authors:  D Alland; A J Steyn; T Weisbrod; K Aldrich; W R Jacobs
Journal:  J Bacteriol       Date:  2000-04       Impact factor: 3.490

Review 5.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

6.  Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

7.  Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.

Authors:  Vincent W-F Tai; Dulce Garrido; Daniel J Price; Andrew Maynard; Jeffrey J Pouliot; Zhiping Xiong; John W Seal; Katrina L Creech; Luz H Kryn; Todd M Baughman; Andrew J Peat
Journal:  Bioorg Med Chem Lett       Date:  2014-04-03       Impact factor: 2.823

8.  Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability.

Authors:  Martin Gengenbacher; Srinivasa P S Rao; Kevin Pethe; Thomas Dick
Journal:  Microbiology       Date:  2009-10-01       Impact factor: 2.777

9.  Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis.

Authors:  Elyse A Dunn; Marina Roxburgh; Lesley Larsen; Robin A J Smith; Alexander D McLellan; Adam Heikal; Michael P Murphy; Gregory M Cook
Journal:  Bioorg Med Chem       Date:  2014-08-07       Impact factor: 3.641

10.  Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.

Authors:  Chao Chen; Susana Gardete; Robert Sander Jansen; Annanya Shetty; Thomas Dick; Kyu Y Rhee; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

View more
  7 in total

Review 1.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

2.  Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against Mycobacterium tuberculosis.

Authors:  Kevin T Fridianto; Ming Li; Kiel Hards; Dereje A Negatu; Gregory M Cook; Thomas Dick; Yulin Lam; Mei-Lin Go
Journal:  J Med Chem       Date:  2021-10-27       Impact factor: 7.446

3.  Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition.

Authors:  Ming Li; Zheng Yen Phua; Yu Xi; Zhujun Xu; Samuel A Nyantakyi; Wei Li; Mary Jackson; Ming Wah Wong; Yulin Lam; Shu Sin Chng; Mei Lin Go; Thomas Dick
Journal:  ACS Infect Dis       Date:  2020-05-29       Impact factor: 5.084

4.  Structural Rigidification of N-Aryl-pyrroles into Indoles Active against Intracellular and Drug-Resistant Mycobacteria.

Authors:  Dorothy Semenya; Meir Touitou; Camila Maringolo Ribeiro; Fernando Rogerio Pavan; Luca Pisano; Vinayak Singh; Kelly Chibale; Georg Bano; Anita Toscani; Fabrizio Manetti; Beatrice Gianibbi; Daniele Castagnolo
Journal:  ACS Med Chem Lett       Date:  2021-12-08       Impact factor: 4.345

5.  Resistance against Membrane-Inserting MmpL3 Inhibitor through Upregulation of MmpL5 in Mycobacterium tuberculosis.

Authors:  Ming Li; Samuel Agyei Nyantakyi; Mei-Lin Go; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 6.  MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections.

Authors:  Jigar P Sethiya; Melanie A Sowards; Mary Jackson; Elton Jeffrey North
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

7.  A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).

Authors:  Martyn Frederickson; Irwin R Selvam; Dimitrios Evangelopoulos; Kirsty J McLean; Mona M Katariya; Richard B Tunnicliffe; Bethany Campbell; Madeline E Kavanagh; Sitthivut Charoensutthivarakul; Richard T Blankley; Colin W Levy; Luiz Pedro S de Carvalho; David Leys; Andrew W Munro; Anthony G Coyne; Chris Abell
Journal:  Eur J Med Chem       Date:  2022-01-11       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.